Opendata, web and dolomites

EPIORGABOLISM SIGNED

Diabetic nephropathy modelling in hESC-derived 3D kidney organoids

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPIORGABOLISM project word cloud

Explore the words cloud of the EPIORGABOLISM project. It provides you a very rough idea of what is the project "EPIORGABOLISM" about.

reprograming    models    differentiation    crispr    human    drug    promoted    chemistry    genes    engineered    treatment    pressure    elucidate    ing    kptcs    tool    drugs    vivo    model    embryonic    progression    validated    montserrat    somatic    blood    mainly    cells    regulators    renal    enhancers    therapies    mimic    patients    serve    fatty    architecture    links    structural    metabolism    epigenetic    good    nephropathy    enzymes    diabetic    diabetes    acid    status    alterations    esrd    pathology    metabolic    oxidation    therapy    therapeutic    date    stop    promoters    kidney    organoids    fibrosis    tissue    proximal    lack    background    preclinical    hypothesize    discovery    recapitulate    encoding    gained    signature    cell    epigenome    stages    disease    glycaemic    methylation    physiological    stem    expertise    impediments    acting    aberrant    tubular    genetic    cas9    molecular    stage    regeneration    reprogramming    dr    dna    functional    dn    occurring    evidences    hesc    vitro    epithelial   

Project "EPIORGABOLISM" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA 

Organization address
address: CARRER BALDIRI REIXAC PLANTA 2A 10-12
city: BARCELONA
postcode: 8028
website: http://www.ibecbarcelona.eu

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-04-18   to  2021-08-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

Diabetic Nephropathy is the leading cause of end-stage renal disease (ESRD). To date, treatment of DN is mainly based on drugs acting on glycaemic and blood pressure control, as there is no validated therapy able to stop the progression towards renal failure. One of the main impediments for developing new therapies for DN has been the lack of a good preclinical model which can recapitulate important functional, structural, and molecular features of advanced human diabetic kidney disease. Here, we aim to develop a DN modelling using human Embryonic Stem Cell (hESC) derived kidney organoids which can recapitulate the in vivo architecture, functionality, and genetic signature of DN. Due to the increasing evidences that links aberrant DNA methylation with kidney fibrosis and metabolic reprograming in DN, we hypothesize that early DN progression is promoted by the metabolic alterations occurring in diabetic patients, resulting in the epigenetic reprogramming of kidney proximal tubular epithelial cells (KPTCs). Based in my background in the fields of metabolism and diabetes, together with the expertise of Dr. Montserrat in the field of somatic reprograming, DN and tissue regeneration/differentiation, this proposal seeks to:1) Elucidate the methylation status of the promoters/enhancers of genes encoding enzymes and regulators of fibrosis and fatty acid oxidation in proximal tubular cells obtained from diabetic patients at different stages of DN progression 2) Establish two in vitro models using hESC-derived kidney organoids; an engineered DN in vitro model, using CRISPR Cas9 to mimic the epigenome signature of DN patients and a physiological DN in vitro model which mimic the diabetic physiological chemistry. The information gained from this DN modelling will offer improved insight into disease pathology and progression. Moreover, it may also serve as a tool for drug discovery to identify therapeutic targets for DN.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIORGABOLISM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIORGABOLISM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

MetEpiC (2020)

P53-dependent Metabolic and Epigenetic Reprogramming in Carcinogenesis

Read More  

EngPTC2 (2019)

Exploring new technologies for the next generation pulse tube cryocooler below 2K

Read More